Anti-HER2 Antibody
| Catalog number: | B2014847 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 20 uL |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Solution |
| Applications: | molecular tool for various biochemical applications |
| Storage: | 2-8C |
| Keywords: | ERBB2 |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Hosseini Ghatar R, Soltantoyeh T, Bahadori M, Khoshnoodi J, Golsaz Shirazi F, Jeddi Tehrani M, Amiri MM, Shokri F. Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro Iran J Immunol. 2017 Sep;14(3):200-214.
- Jurianz K, Maslak S, Garcia-Schler H, Fishelson Z, Kirschfink M. Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2 Immunopharmacology. 1999 May;42(1-3):209-18.
- Xu Y, Wang Y, Gong J, Zhang X, Peng Z, Sheng X, Mao C, Fan Q, Bai Y, Ba Y, Jiang D, Yang F, Qi C, Li J, Wang X, Zhou J, Lu M, Cao Y, Yuan J, Liu D, Wang Z, Fang J, Shen L. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors Gastric Cancer. 2021 Jul;24(4):913-925.
- Takei J, Asano T, Tanaka T, Sano M, Hosono H, Nanamiya R, Tateyama N, Saito M, Suzuki H, Harada H, Kaneko MK, Kato Y. Development of a Novel Anti-HER2 Monoclonal Antibody H(2)Mab-181 for Gastric Cancer Monoclon Antib Immunodiagn Immunother. 2021 Aug;40(4):168-176.
- Asano T, Takei J, Suzuki H, Kaneko MK, Kato Y. Epitope Mapping of an Anti-HER2 Monoclonal Antibody (H(2)Mab-181) Using Enzyme-Linked Immunosorbent Assay Monoclon Antib Immunodiagn Immunother. 2021 Dec;40(6):255-260.
- Amiri MM, Golsaz-Shirazi F, Soltantoyeh T, Hosseini-Ghatar R, Bahadori T, Khoshnoodi J, Navabi SS, Farid S, Karimi-Jafari MH, Jeddi-Tehrani M, Shokri F. Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition Invest New Drugs. 2018 Apr;36(2):171-186.
- Zeng J, Zhang H, Guan R. Bioactivity of recombinant humanized monoclonal antibody against HER2 in-vivo and in-vitro and its mechanism of action in ovarian cancer Transl Cancer Res. 2023 Jun 30;12(6):1565-1576.
- Dank M. [Human recombinant anti-HER2 monoclonal antibodya new targeted treatment in breast cancer] Orv Hetil. 2001 Nov 18;142(46):2563-8.
- Ramezani-Aliakbari K, Khaki-Bakhtiarvand V, Mahmoudian J, Asgarian-Omran H, Shokri F, Hojjat-Farsangi M, Jeddi-Tehrani M, Shabani M. Evaluation of the anti-tumor effects of an anti-Human Epidermal growth factor receptor 2 (HER2) monoclonal antibody in combination with CD11b(+)/Gr-1(+) myeloid cells depletion using a recombinant peptibody in 4 T1-HER2 tumor model Int Immunopharmacol. 2023 Aug;121:110463.
